DK3097086T3 - (2s)-n-[(1s)-1-cyan-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidyl-peptidase i-hæmmere - Google Patents

(2s)-n-[(1s)-1-cyan-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidyl-peptidase i-hæmmere Download PDF

Info

Publication number
DK3097086T3
DK3097086T3 DK15701577.7T DK15701577T DK3097086T3 DK 3097086 T3 DK3097086 T3 DK 3097086T3 DK 15701577 T DK15701577 T DK 15701577T DK 3097086 T3 DK3097086 T3 DK 3097086T3
Authority
DK
Denmark
Prior art keywords
carboxamide
ethyl
phenyl
oxazepan
oxo
Prior art date
Application number
DK15701577.7T
Other languages
English (en)
Inventor
Hans Roland Loenn
Stephen Connolly
Steven Swallow
Staffan Po Karlsson
Carl Johan Aurell
John Fritiof Ponten
Kevin James Doyle
Graham Peter Jones
David Wyn Watson
Jaqueline Anne Macritchie
Nicholas John Palmer
De Poël Amanda Jane Van
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3097086(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3097086T3 publication Critical patent/DK3097086T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (11)

1. Forbindelse med formlen (I) hvor
R1 e
R2 er udvalgt fra hydrogen, F, Cl, Br, OSO2C1-3-alkyl, eller Ci-3-alkyl; R3 er udvalgt fra hydrogen, F, Cl, Br, CN, CF3, SC>2Ci-3-alkyl, CONH2 eller S02NR4R5, hvor R4 og R5 sammen med det nitrogenatom, hvortil de er bundet, danner en azetidin-, pyrrolidin- eller piperidinring; eller R1 er udvalgt fra
X er udvalgt fra O, S eller CF2; Y er udvalgt fra O eller S; Q er udvalgt fra CH eller N; R6 er udvalgt fra Ci-3-alkyl, hvor Ci-3-alkyl eventuelt er substitueret med 1, 2 eller 3 F og eventuelt med én substituent udvalgt fra OH, OCi-3-alkyl, N(Ci-3-alkyl)2, cyclopropyl eller tetrahydropyran; R7 er udvalgt fra hydrogen, F, Cl eller CH3; eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1, hvor R1 er
eller et farmaceutisk acceptabelt salt deraf.
3. Forbindelse ifølge enten krav 1 eller krav 2, hvor X er O; R6 er C i-3-alkyl; og R7 er hydrogen; eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse med formlen (I) ifølge krav, der er udvalgt fra: (25)-/Y-[(15)-1 -cyan-2-(4'-cyanobiphcnyl-4-yl)cthyl]-l,4-oxazepan-2-carboxamid; (2S)-N- j( 15)-1-cyan-2-[4-(3-methyl-2-oxo-2,3-dihydro-l ,3-bcnzoxazol-5-yl)phcnyl Jethyl}-1,4 -oxazepan-2-carboxamid; (25)-iV-{( 15)-1-cyan-2-[4-(3,7-dimcthyl-2-oxo-2,3-dihydro-1 ,3-benzoxazol-5-yl)phcnyl]ethyl} -1,4-oxazepan-2-carboxamid; 4'-[(25)-2-cyan-2-{[(25)-l,4-oxazepan-2-ylcarbonyl]amino}ethyl]biphenyl-3-yl methansulfonat; (2S)-N- {(15)-1 -cyan-2-[4-(3-methyl-l ,2-benzoxazol-5-yl)phenyl]ethyl} -1,4-oxazepan-2-carbo xamid; (:2S)-N- {(1 S)-1 -cyan-2-[4'-(trifluormethyl)biphenyl-4-yl]ethyl} -1,4-oxazepan-2-carboxamid; (25)-/V-[(15)-l-cyan-2-(3',4'-difluorbiphenyl-4-yl)ethyl]-l,4-oxazepan-2-carboxamid; (2 S)-N- {(15)-1 -cyan-2-[4-(6-cyanopyridin-3-yl)phenyl]ethyl} -1,4-oxazepan-2-carboxamid; (25)-/V-{(15)-l-cyan-2-[4-(4-mcthyl-3-oxo-3,4-dihydro-2//-l,4-benzothiazin-6-yl)phenyl]ethyl } -1,4-oxazepan-2-carboxamid; (25)-/V-{(15)-l-cyan-2-[4-(3-cthyl-7-mcthyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)phenyl]et hyl} -1,4-oxazepan-2-carboxamid; (25)-A'-[(15)-1 -cyan-2- (4-[3-(2-hydroxy-2-methylpropyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5 -yljphenyl} ethyl]-1,4-oxazepan-2-carboxamid; (25)-jV-[(15)-l-cyan-2-{4-[3-(2,2-difluorethyl)-7-fluor-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl] phenyl} ethyl]-l ,4-oxazepan-2-carboxamid; (25)-/Y-[( 1 5)-1 -cyan-2-(4- {3-[2-(dimethylamino)ethyl]-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl }phenyl)ethyl]-1,4-oxazepan-2-carboxamid; (2 S)-N- {(15)-1 -cyan-2-[4-(3,3-difluor-1 -methyl-2-oxo-2,3-dihydro-1 /7-indol-6-yl)phcnyl]cthyl } -1,4-oxazepan-2-carboxamid; (2S)-N- {(1 S)-1 -cyan-2-[4-(7-fluor-3-methyl-2-oxo-2,3-dihydro-l ,3-bcnzoxazol-5-yl)phcnyl]ct hyl} -1,4-oxazepan-2-carboxamid; (25)-iV-{(15)-l-cyan-2-[4-(3-ethyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)phenyl]ethyl}-l,4-o xazepan-2-carboxamid; (25)-iV-[(15)-l-cyan-2-{4-[3-(cyclopropylmethyl)-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl]phe nyl} ethyl] -1,4-oxazepan-2-carboxamid; (25)-7V-[(15)-1 -cyan-2- {4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl]pheny 1} ethyl] -1,4-oxazepan-2-carboxamid; (25)-iV-[(15)-1-cyan-2-{4-[2-oxo-3-(propan-2-yl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl} eth yl]-1,4-oxazepan-2-carboxamid; (25)-.V-{( 15)-1-cyan-2-[4-(4-methyl-3-oxo-3,4-dihydro-2//-l,4-benzoxazin-6-yl)phenyl]ethyl} -1,4-oxazepan-2-carboxamid; (25)-7V-[(l 5)-1 -cyan-2-{4-[3-(2-mcthoxycthyl)-2-oxo-2,3-dihydro-l ,3-benzoxazol-5-yl]phcnyl } ethyl] -1,4-oxazepan-2-carboxamid; (25)-77- i (1 S)-1 -cyan-2-[4-(5-cyanothiophcn-2-yl)phcnyl]cthyl} -1,4-oxazepan-2-carboxamid; (25)-7V-[(15)-2-(4'-carbamoyl-3'-fluorbiphcnyl-4-yl)-l -cyanocthyl]-l,4-oxazepan-2-carboxami d; (2 S)-N- {(15)-1 -cyan-2-[4-(l -methyl-2-oxo-1,2-dihydroquinolin-7-yl)phenyl] ethyl} -1,4-oxazep an-2-carboxamid; (25)-7V-[(15)-1 -cyan-2- {4-[2-oxo-3-(tctrahydro-2//-pyran-4-ylmcthyl)-2,3-dihydro-1,3-benzox azol-5-yl]phenyl}ethyl]-l,4-oxazepan-2-carboxamid; (25)-.V-{(15)-2-[4-(7-chlor-3-methyl-2-oxo-2,3-dihydro-l ,3-bcnzoxazol-5-yl)phcnyl]-l-cyanoc thyl} -1,4-oxazepan-2-carboxamid; (25)-.V-[( 15)-1 -cyan-2- {4-[3-(2,2-difluorethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl } ethyl] -1,4-oxazepan-2-carboxamid; (25)-.V-[( 15)-1 -cyan-2- {4-[2-oxo-3-(2,2,2-trifluorethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phen yl} ethyl] -1,4-oxazepan-2-carboxamid; (25)-/V-{( 15)-l-cyan-2-[4-(3-methyl-2-oxo-2,3-dihydro-l ,3-bcnzothiazol-5-yl)phcnyl]cthyl}-l, 4-oxazepan-2-carboxamid; (25)-A-{(15)-1 -cyan-2-[4'-(mcthylsulfonyl)bi phenyl-4-yl]ethyl}-l,4-oxazcpan-2-carboxam id; (2S)-N-{( 15)-2-[4'-(azetidin-1 -ylsulfonyl)biphcnyl-4-yl]-1 -cyanoethyl } -1,4-oxazcpan-2-carbox amid; (25)-7V-[( 1 S)-1 -cyan-2-(4'-fluorbiphcnyl-4-yl)cthyl]- l,4-oxazepan-2-carboxamid; (25)-./V-{(15)-2-[4-(l,3-benzothiazol-5-yl)phenyl]-l-cyanoethyl}-l,4-oxazepan-2-carboxamid; (25)-/V-[( 1 S)-1 -cyan-2-(4'-cyanbiphcnyl-4-yl)cthyl]-1,4-oxazcpan-2-carboxamid og farmaceutisk acceptable salte deraf.
5. Forbindelse ifølge krav 1, der er (25)-vV-{(15)-l-cyan-2-[4-(3-methyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)phenyl]ethyl}-l,4 -oxazepan-2-carboxamid
eller et farmaceutisk acceptabelt salt deraf.
6. Forbindelse ifølge krav 1, der er (25)-/V-{(15)-l-cyan-2-[4-(3-mcthyl-2-oxo-2,3-dihydro-l,3-benzoxazol-5-yl)phenyl]ethyl}-l,4 -oxazepan-2-carboxamid
7. Farmaceutisk sammensætning, der omfatter en forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 6 og et farmaceutisk acceptabelt adjuvans, fortyndingsmiddel eller bærestof.
8. Forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 6 til anvendelse i terapi.
9. Forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 6, til anvendelse i behandling af obstruktive luftvejssygdomme: herunder en hvilken som helst af astma, der indbefatter bronkial, allergisk, intrinsisk, ekstrinsisk, anstrengelsesinduceret, lægemiddelinduceret (herunder aspirin- og NSAID-induceret) og støvinduceret astma, begge intermitterende og vedvarende og af enhver alvorsgrad, og andre årsager til luftvejs hyperresponsivitet; kronisk obstruktiv lungesygdom (COPD); bronkitis, herunder infektiøs og eosinofil bronkitis; emfysem; bronkiektasi; cystisk fibrose; sarkoidose; alpha-l-antitrypsindeficiens; tærskerlunge og beslægtede sygdomme; hypersensibilitetspneumonitis; lungefibrose, herunder kryptogen fibrøs alveolitis, idiopatiske interstitielle pneumonier, fibrose, der komplicerer antineoplastisk terapi og kronisk infektion, herunder tuberkulose og aspergillose og andre svampeinfektioner; komplikationer ved lungetransplantation; vaskulitiske og trombotiske forstyrrelser i lungevaskulatur, og pulmonal hypertension; hostestillende aktivitet, der indbefatter behandling af kronisk hoste forbundet med inflammatoriske og sekretoriske luftvejstilstande, og iatrogen hoste; akut og kronisk rhinitis, herunder rhinitis medicamentosa, og vasomotor rhinitis; stadig tilbagevendende og sæsonbetinget allergisk rhinitis, herunder rhinitis nervosa (høfeber); næsepolypose; akut virusinfektion, herunder almindelig forkølelse, og infektion på grund af respiratorisk syncytialvirus, influenza, coronavirus (herunder SARS) og adenovirus, akut lungelæsion, ARDS (adult respiratory distress syndrome), såvel som exacerbationer af hver af de foregående luftvejssygdomstilstande, navnlig exacerbationer af samtlige typer af astma eller COPD.
10. Forbindelse med formlen (I) til anvendelse ifølge krav 9 til anvendelse i behandling af astma eller kronisk obstruktiv lungesygdom.
11. Kombination af en forbindelse med formlen (I) ifølge et hvilket som helst af kravene 1 til 6 og ét eller flere midler, der er uafhængigt udvalgt fra: • en ikke-steroid glucocorticoidreceptoragonist; • en selektiv P2-adrenoceptoragonist; • en phosphodiesterasehæmmer; • en proteasehæmmer; • et glucocorticoid; • et anticholinergt middel; • en modulator af kemokinreceptorfunktion og • en hæmmer af kinasefunktion.
DK15701577.7T 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyan-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidyl-peptidase i-hæmmere DK3097086T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
PCT/GB2015/050155 WO2015110826A1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
DK3097086T3 true DK3097086T3 (da) 2018-02-05

Family

ID=52432834

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15701577.7T DK3097086T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyan-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidyl-peptidase i-hæmmere
DK20173862.2T DK3744714T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
DK17195612.1T DK3323814T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK20173862.2T DK3744714T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere
DK17195612.1T DK3323814T3 (da) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepan-2-carboxamider som dipeptidylpeptidase i-hæmmere

Country Status (39)

Country Link
US (19) US9522894B2 (da)
EP (4) EP3744714B1 (da)
JP (8) JP6469711B2 (da)
KR (1) KR102417684B1 (da)
CN (2) CN110483492B (da)
AP (1) AP2016009322A0 (da)
AR (1) AR099177A1 (da)
AU (4) AU2015208932C1 (da)
BR (1) BR112016016224B1 (da)
CA (1) CA2935625C (da)
CL (1) CL2016001889A1 (da)
CR (1) CR20160327A (da)
CY (2) CY1120049T1 (da)
DK (3) DK3097086T3 (da)
DO (1) DOP2016000175A (da)
EA (1) EA032794B1 (da)
ES (3) ES2808060T3 (da)
FI (2) FI3744714T3 (da)
HK (1) HK1225730B (da)
HR (3) HRP20250302T1 (da)
HU (3) HUE052421T2 (da)
IL (3) IL246614B (da)
LT (3) LT3744714T (da)
MX (1) MX368840B (da)
MY (1) MY194850A (da)
NO (1) NO2699580T3 (da)
NZ (2) NZ722063A (da)
PE (1) PE20161218A1 (da)
PH (1) PH12016501439A1 (da)
PL (3) PL3323814T3 (da)
PT (3) PT3097086T (da)
RS (3) RS56919B1 (da)
SG (2) SG10201701056QA (da)
SI (3) SI3323814T1 (da)
SM (3) SMT201800058T1 (da)
TW (1) TWI690517B (da)
UY (1) UY35963A (da)
WO (1) WO2015110826A1 (da)
ZA (2) ZA201605856B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (da) 2014-01-24 2018-02-24
KR20240091302A (ko) * 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
HUE070049T2 (hu) 2018-03-01 2025-05-28 Astrazeneca Ab (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
US20210252015A1 (en) * 2018-07-17 2021-08-19 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
WO2020018547A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
BR112022007623A2 (pt) * 2019-10-23 2022-07-12 Chong Kun Dang Pharmaceutical Corp Composições para prevenir ou tratar doenças pulmonares obstrutivas crônicas (dpoc)
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
EP4182700A4 (en) 2020-07-20 2024-11-13 Insmed Incorporated METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATMENT OF DIPETIDYL PEPTIDASE-1-MEDIATED DISEASES
CN115996923B (zh) 2020-08-26 2025-07-18 海思科医药集团股份有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
KR20230117738A (ko) * 2020-12-04 2023-08-09 레이스톤 바이오파마 컴퍼니 리미티드 카텝신 c의 소분자 억제제 및 이의 의약적 용도
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane
US20240226112A1 (en) * 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CA3236069A1 (en) * 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937B (zh) * 2021-12-23 2026-04-10 杭州邦顺制药股份有限公司 二肽基肽酶ⅰ抑制剂及其用途
EP4450497A4 (en) * 2022-01-11 2025-11-26 Shanghai Yidian Pharmaceutical Tech Development Co Ltd NITRILE PEPTIDYL COMPOUND AND ITS USES
EP4479059A4 (en) * 2022-02-16 2026-01-28 Insmed Inc CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE
TW202333739A (zh) * 2022-02-22 2023-09-01 大陸商四川海思科製藥有限公司 二肽基肽酶1抑制劑多晶型物及其製備方法和用途
JP2025508792A (ja) * 2022-02-22 2025-04-10 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態
IL314855A (en) * 2022-02-22 2024-10-01 Haisco Pharmaceuticals Pte Ltd Preparation method of nitrogen-containing heterocyclic compound
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
EP4538271A4 (en) * 2022-06-07 2025-10-08 Reistone Biopharma Company Ltd POLYMORPH OF BENZO[C]CHROMANE COMPOUND, ITS PREPARATION METHOD AND ITS USE
TW202404961A (zh) * 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并［ｃ］色滿化合物的可藥用鹽、其多晶型及用途
AU2023296161A1 (en) 2022-06-13 2025-01-02 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound
EP4551554A1 (en) 2022-07-06 2025-05-14 Chiesi Farmaceutici S.p.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
EP4602043A1 (en) 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
JP2026503035A (ja) * 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途
JP2026507449A (ja) * 2023-02-15 2026-03-04 インスメッド インコーポレイテッド Ｄｐｐ１阻害剤としてのある特定の１，４－オキサゼパン－２－カルボキサミドの使用
JP2026510407A (ja) * 2023-03-23 2026-04-02 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ小分子阻害剤を含む医薬組成物
AU2024340032A1 (en) * 2023-09-15 2026-04-09 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
WO2025250560A1 (en) * 2024-05-28 2025-12-04 Insmed Incorporated Methods for treating bronchiectasis

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
CA2422057C (en) 2000-09-08 2012-11-27 Prozymex A/S Dipeptidyl peptidase i crystal structure and its uses
BR0114436A (pt) * 2000-10-06 2003-07-01 Tanabe Seiyaku Co Composto com anel de cinco elementos contendo nitrogênio alifático
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
HUP0402344A2 (hu) 2001-12-04 2005-02-28 F. Hoffmann-La Roche Ag Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
EP1633702B1 (en) 2003-05-30 2008-07-02 Prozymex A/S Protease inhibitors
JP2006527704A (ja) * 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
EP3372614B1 (en) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1745292A2 (en) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
PL1916994T3 (pl) 2004-06-29 2014-05-30 Takeda Pharma As Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
WO2007005668A2 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
JP2010520293A (ja) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 複素環式部分を含有するメタロプロテアーゼ阻害剤
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
MX2010003263A (es) 2007-09-25 2010-06-02 Novartis Ag Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina.
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
JP5752601B2 (ja) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
BRPI1016132B8 (pt) 2009-04-01 2021-05-25 Bial Portela & Ca Sa composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
MX2011011661A (es) * 2009-05-07 2011-11-18 Astrazeneca Ab Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
US8841463B2 (en) 2011-02-11 2014-09-23 Glaxosmithkline Intellectual Property Development Limited Cathepsin C inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
CN104114557B (zh) 2012-02-21 2017-10-24 默克专利股份公司 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
EP2840083B1 (en) 2012-04-17 2017-09-13 Astellas Pharma Inc. Nitrogenated bicyclic aromatic heterocyclic compound
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
JP6437929B2 (ja) 2013-03-14 2018-12-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
EP2970228B1 (en) 2013-03-14 2017-05-10 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
EP2970252B1 (en) 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2015027039A1 (en) 2013-08-22 2015-02-26 Emory University Devices and methods related to airway inflammation
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
EP3044214B1 (en) 2013-09-09 2017-08-09 ProZymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (da) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
EP3129020A1 (en) 2014-04-10 2017-02-15 Novartis AG S1p modulator immediate release dosage regimen
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
WO2015180687A1 (en) 2014-05-30 2015-12-03 The University Of Hong Kong Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
EP3511331A1 (en) 2014-09-12 2019-07-17 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
JP6783426B2 (ja) 2015-03-05 2020-11-11 ニュープロザイム・セラピューティクス・アンパルトセルスカブＮｅｕｐｒｏｚｙｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡｐＳ ジペプチジルペプチダーゼｉ阻害剤としてのペプチジルニトリル化合物
KR20240091302A (ko) 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
HUE070049T2 (hu) 2018-03-01 2025-05-28 Astrazeneca Ab (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
US20210252015A1 (en) 2018-07-17 2021-08-19 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
WO2020018547A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
MX2021012548A (es) 2019-04-17 2023-01-05 Azora Therapeutics Inc Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
US20240226112A1 (en) 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
CA3236069A1 (en) 2021-10-29 2023-05-04 Ariel Teper Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
EP4479059A4 (en) 2022-02-16 2026-01-28 Insmed Inc CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE

Also Published As

Publication number Publication date
JP7336563B2 (ja) 2023-08-31
US20230025351A1 (en) 2023-01-26
MX2016009349A (es) 2016-10-13
LT3097086T (lt) 2018-02-26
JP6469711B2 (ja) 2019-02-13
JP2021046423A (ja) 2021-03-25
PH12016501439B1 (en) 2017-02-06
EP3323814B1 (en) 2020-05-13
AU2015208932B8 (en) 2017-03-09
AU2019202675A1 (en) 2019-05-16
DK3323814T3 (da) 2020-08-03
CN110483492B (zh) 2023-07-21
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
KR102417684B1 (ko) 2022-07-05
AU2015208932C1 (en) 2017-05-25
AU2018202956B2 (en) 2019-05-09
EP4548972A3 (en) 2025-06-25
US20230085620A1 (en) 2023-03-23
JP2025072423A (ja) 2025-05-09
PT3323814T (pt) 2020-08-05
US20230069044A1 (en) 2023-03-02
CN105980367A (zh) 2016-09-28
ES2658516T3 (es) 2018-03-12
US12054465B2 (en) 2024-08-06
JP2025157389A (ja) 2025-10-15
CY1120049T1 (el) 2018-12-12
LT3323814T (lt) 2020-10-26
US20230116721A1 (en) 2023-04-13
HRP20180116T1 (hr) 2018-03-23
WO2015110826A1 (en) 2015-07-30
HK1255870A1 (en) 2019-08-30
US11655222B2 (en) 2023-05-23
CN105980367B (zh) 2019-08-23
SMT202500137T1 (it) 2025-05-12
CA2935625C (en) 2022-10-18
RS60639B1 (sr) 2020-09-30
US20200017455A1 (en) 2020-01-16
US20150210655A1 (en) 2015-07-30
EP3323814A1 (en) 2018-05-23
IL252836A0 (en) 2017-08-31
PT3744714T (pt) 2025-04-07
SI3744714T1 (sl) 2025-05-30
NZ722063A (en) 2017-09-29
US20240132455A1 (en) 2024-04-25
SG10201701056QA (en) 2017-03-30
PE20161218A1 (es) 2016-11-27
EP3097086B1 (en) 2017-12-13
US20230033573A1 (en) 2023-02-02
SI3097086T1 (en) 2018-04-30
JP2017503832A (ja) 2017-02-02
NZ734768A (en) 2022-09-30
AU2015208932B2 (en) 2017-02-16
CN110483492A (zh) 2019-11-22
ZA201800431B (en) 2019-09-25
JP7628587B2 (ja) 2025-02-10
AP2016009322A0 (en) 2016-07-31
US11673872B2 (en) 2023-06-13
ES3018635T3 (es) 2025-05-16
US20230028726A1 (en) 2023-01-26
MX368840B (es) 2019-10-18
PL3744714T3 (pl) 2025-09-08
AU2018202956A1 (en) 2018-05-17
NO2699580T3 (da) 2018-02-24
US11655223B2 (en) 2023-05-23
EA201691375A1 (ru) 2017-01-30
US11680049B2 (en) 2023-06-20
AR099177A1 (es) 2016-07-06
FIC20265009I1 (fi) 2026-04-18
RS66709B1 (sr) 2025-05-30
AU2015208932A1 (en) 2016-07-28
KR20160111470A (ko) 2016-09-26
PL3097086T3 (pl) 2018-04-30
CA2935625A1 (en) 2015-07-30
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
AU2019202675B2 (en) 2020-05-28
PL3323814T3 (pl) 2020-10-19
CL2016001889A1 (es) 2016-12-09
JP2026065113A (ja) 2026-04-14
EP4548972A2 (en) 2025-05-07
EA032794B1 (ru) 2019-07-31
US10669245B2 (en) 2020-06-02
US20230278969A1 (en) 2023-09-07
HRP20250302T1 (hr) 2025-04-25
EP3744714B1 (en) 2025-01-15
HUE070606T2 (hu) 2025-06-28
US20200247765A1 (en) 2020-08-06
HK1225730B (en) 2017-09-15
US20170057938A1 (en) 2017-03-02
US9522894B2 (en) 2016-12-20
JP2022096662A (ja) 2022-06-29
US11655221B2 (en) 2023-05-23
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
US20230115170A1 (en) 2023-04-13
US9815805B2 (en) 2017-11-14
US10287258B2 (en) 2019-05-14
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
JP2019070029A (ja) 2019-05-09
US11117874B2 (en) 2021-09-14
DOP2016000175A (es) 2016-08-15
SI3323814T1 (sl) 2020-10-30
LT3744714T (lt) 2025-04-10
AU2015208932A8 (en) 2017-03-09
BR112016016224B1 (pt) 2023-02-23
SG11201606052TA (en) 2016-08-30
PH12016501439A1 (en) 2017-02-06
US11673871B2 (en) 2023-06-13
US20230062646A1 (en) 2023-03-02
US20210238152A1 (en) 2021-08-05
US20180251436A1 (en) 2018-09-06
SMT201800058T1 (it) 2018-03-08
US11667615B2 (en) 2023-06-06
AU2017200338A1 (en) 2017-02-02
JP2023156479A (ja) 2023-10-24
JP6804570B2 (ja) 2020-12-23
JP7714823B2 (ja) 2025-07-29
EP3097086A1 (en) 2016-11-30
US20240336582A1 (en) 2024-10-10
AU2017200338B2 (en) 2018-03-01
HRP20201147T1 (hr) 2020-12-11
MY194850A (en) 2022-12-19
US20260055067A1 (en) 2026-02-26
US11814359B2 (en) 2023-11-14
JP7157791B2 (ja) 2022-10-20
US11655224B2 (en) 2023-05-23
CR20160327A (es) 2016-10-20
DK3744714T3 (da) 2025-04-07
EP3744714A1 (en) 2020-12-02
TW201612167A (en) 2016-04-01
HUE052421T2 (hu) 2021-04-28
CY1123391T1 (el) 2021-12-31
TWI690517B (zh) 2020-04-11
US20230250071A1 (en) 2023-08-10
ZA201605856B (en) 2020-02-26
SMT202000433T1 (it) 2020-09-10
BR112016016224A2 (da) 2017-08-08
IL265611A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US11655222B2 (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
HK1225730A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
HK40120007A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
HK40042394A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
HK1255870B (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors